Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q1 2024 · 10-Q
Revenue$89.44K$89.44K— vs Q1 2023 Net Income-$178.52K-$178.52KN/M vs Q1 2023 EPS Diluted-$0.01-$0.01N/M vs Q1 2023 Operating Income-$171,900N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
Margins · derivedOperating margin-192.2%
Net margin-199.6%
ended Nov 30, 2023 · filed Jan 12, 2024 · 43 d after period end